Newly appointed Zealand Pharma CEO says commercial organization was too expensive

Going forward, Zealand Pharma’s revenue will come from strategic partnerships, which is why the company is significantly reducing its commercial unit and workforce in the US. It’s too expensive to have a commercial department with few products on the market, says Adam Steensberg, the company’s new CEO.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by christopher due karlsson, translated by daniel pedersen

Having spent a lot of funds the past few years on building up an commercial organization in the US, biotech company Zealand Pharma has decided to change lanes completely.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading